In an effort to expand its cash runway beyond 12 months, Prime Medicines has signed a deal with Bristol Myers Squibb worth a ...

Six months after treatment with the radiopharmaceutical therapy, 77.8% of patients with meningioma were alive and had not ...

Johnson & Johnson linked Carvykti to a 45% reduction in risk of death and Darzalex to a 61% improvement in minimal residual ...

One upcoming decision—on a perioperative PD-1 regimen for lung cancer—comes as the FDA considers an overhaul of trial designs in this treatment setting.